hepatorenal syndrome has the worst and parenchymal nephropathy -the relatively best prognosis. Prerenal failure and hepatorenal syndrome are among the most common causes of renal insufficiency in liver disease. In these patients, portal hypertension and splanchnic vasodilatation causes a shift in blood volume away from the central circulation. This reduction of centrally effective blood volume induces a stimulation of counter-regulatory mechanisms such as activation of renin-aldosterone and of the sympathetic nervous system. This results in renal sodium retention, functional renal failure and ascites formation. Therefore, marked, fast decreases of plasma volume must be avoided in the treatment of ascites [1] .
Large volume paracentesis can induce circulatory dysfunction, resulting in renal failure. Albumin infusion following paracentesis has been impressively shown to reduce circulatory dysfunction and to improve survival [2] . Therefore, most guidelines recommend albumin infusion following large volume paracentesis in patients with cirrhosis. For patients with massive ascites, transjugular intrahepatic portosystemic shunt (TIPS) provides good control of ascites and reduces the number of paracentesis. Moreover, TIPS improves survival in these patients. For these beneficial effects, selection of suitable patients is crucial. Therefore, patients with serum bilirubin >5 mg/ dl or pre-existing hepatic encephalopathy should not be TIPS candidates [3] .
While beta-blockers reduce portal pressure and therefore the risk of variceal bleeding, they also decrease cardiac output and may impair renal perfusion. A retrospective study reported an increase of mortality risk in patients with refractory ascites receiving beta-blockers [4] . This was not confirmed by another report [5] in which the patients received a lower mean daily propranolol dose than in the afore-mentioned study (49 vs. 113 mg/day). Untoward effects of beta-blockers may indeed be mediated by their effect on mean arterial pressure. Patients with spontaneous bacterial peritonitis may be particularly prone to develop hypotension when receiving beta-blockers. This effect has been shown to be linked with survival: while patients with spontaneous bacterial peritonitis had an increased mortality risk, this was not the case in patients undergoing paracentesis without spontaneous bacterial peritonitis [6] . A recent prospective study has shown that non-selective betablockers (NSBB) improve survival probability of patients with ascites on the transplant waiting list [7] . Interestingly, patients receiving Carvedilol had less benefit than patients receiving propranolol ( fig. 1 ). This may be due to a more marked effect of Carvedilol on systemic arterial pressure. Altogether, the use of beta-blockers and particularly the dosage should be judiciously estimated, particularly in patients with spontaneous bacterial peritonitis [8] or patients with low systolic blood pressure.
Hepatorenal syndrome, particularly type I has a detrimental prognosis [9] . Recent studies have shown that administration of terlipressin plus albumin can improve re- nal function in patients with hepatorenal syndrome type 1 and can reduce short-term mortality [10] . However, time to response is rather long and the traditional definition of hepatorenal syndrome has been questioned as a prerequisite for starting innovative treatments. Recently, a proposal to broaden the diagnosis of renal dysfunction in cirrhosis has been put forward [11] . It includes cases of acute and chronic renal failure not meeting the diagnostic criteria of hepatorenal syndrome types 1 and 2, respectively. Rather acute kidney injury (AKI), similarly as in patients without cirrhosis should include all causes of acute deterioration of renal function as indicated by an increase of serum creatinine by >50% from baseline or a rise of ≥ 0.3 mg/dl within few days. Such renal dysfunction is a defining feature of acute-on-chronic liver failure [12] .
Interestingly, patients characterized by such minor renal dysfunction over time exhibit a continuous increase of serum creatinine and a decrease of mean arterial pressure [13] . Consequently, mortality risk has been shown increased in these patients ( fig. 2 ) . Based on such observations, the International Club of Ascites has established new definitions for the diagnosis and management of AKI in patients with cirrhosis [14] ( table 1 ) . Indeed, the stage of AKI is a predictor of survival in these patients [15] ( fig. 3 ).
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